Aging, Geriatric Syndromes and Clonal Hematopoiesis
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 50 - Any |
| Updated: | 5/2/2018 |
| Start Date: | March 10, 2016 |
| End Date: | April 30, 2030 |
| Contact: | Tanya Wildes, M.D. |
| Email: | twildes@wustl.edu |
| Phone: | 314-362-5817 |
In this study the investigators will incorporate a wide range of clinical variables
associated with aging to determine whether they are associated with mutation status
independent of chronologic age. Clinically, aging can be operationalized using geriatric
assessment, which entails a comprehensive multi-dimensional assessment of the health of an
older adult, including measures of comorbidity, polypharmacy, functional status, cognition,
depression, falls, social activities and social support. Given that aging is heterogeneous,
geriatric assessment allows greater specificity for aging than chronological age alone.
associated with aging to determine whether they are associated with mutation status
independent of chronologic age. Clinically, aging can be operationalized using geriatric
assessment, which entails a comprehensive multi-dimensional assessment of the health of an
older adult, including measures of comorbidity, polypharmacy, functional status, cognition,
depression, falls, social activities and social support. Given that aging is heterogeneous,
geriatric assessment allows greater specificity for aging than chronological age alone.
Inclusion Criteria:
- At least 50 years of age.
- At least 110 pounds.
- Able to understand written and spoken English.
- Able to understand and willing to sign an IRB-approved written informed consent
document.
Exclusion Criteria:
- Inability or unwillingness to complete health questionnaire.
- History of a recent (<30 days) acute viral illness.
- Current cancer diagnosis and currently receiving chemotherapy or undergoing radiation
therapy. A prior history of cancer is allowed if the participant completed therapy > 1
year prior to enrollment; participants with a prior diagnosis of cancer will be asked
to sign a release of information for the research team to obtain records regarding
their prior cancer treatment.
- Current use of drugs that cause DNA damage (e.g. Cytoxan, azathioprine, etc.) for the
treatment of a non-malignant disease.
- Vulnerable populations (e.g. prisoners).
- Known infection with Hepatitis B or C, HTLV, or HIV.
We found this trial at
1
site
660 S Euclid Ave
Saint Louis, Missouri 63110
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Tanya Wildes, M.D.
Phone: 314-362-5817
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
Click here to add this to my saved trials
